

ASX RELEASE

24 June 2022

Registered Office and Principal Place of Business

Amplia Therapeutics Limited (ASX: **ATX**) (**Amplia** or **the Company**) advises that it has changed its Registered Office and Principal Place of Business to:

Level 17, 350 Queen St,
Melbourne VIC 3000
AUSTRALIA

This ASX announcement was approved and authorised for release by the Chief Executive Officer.

For Further Information

Dr. John Lambert
Chief Executive Officer
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

- ENDS -